AR123132A1 - Formas cristalinas de un inhibidor de la o-glucoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa - Google Patents
Formas cristalinas de un inhibidor de la o-glucoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasaInfo
- Publication number
- AR123132A1 AR123132A1 ARP210102157A ARP210102157A AR123132A1 AR 123132 A1 AR123132 A1 AR 123132A1 AR P210102157 A ARP210102157 A AR P210102157A AR P210102157 A ARP210102157 A AR P210102157A AR 123132 A1 AR123132 A1 AR 123132A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical composition
- compound
- formula
- glucopyranosidase
- desoxy
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 239000007787 solid Substances 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- JYOIEMUTUIWZPL-GXSJLCMTSA-N N-[4-fluoro-5-[[(2S,4R)-4-(6-methoxypyrimidin-4-yl)oxy-2-methylpyrrolidin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide Chemical compound C[C@H]1C[C@H](CN1CC2=C(N=C(S2)NC(=O)C)F)OC3=NC=NC(=C3)OC JYOIEMUTUIWZPL-GXSJLCMTSA-N 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
En la presente se describen formas sólidas de N-(4-fluoro-5-(((2S,4R)-4-((6-metoxipirimidin-4-il)oxi)-2-metilpirrolidin-1-il)metil)tiazol-2-il)acetamida, compuesto de fórmula (1) y el proceso de elaboración de dichas formas sólidas del compuesto de fórmula (1). La presente invención además se refiere a una composición farmacéutica que comprende la Forma A y la Forma B cristalinas del compuesto de fórmula (1), y métodos para usar dicha forma y composición farmacéutica en el tratamiento y prevención de la enfermedad de Alzheimer y trastornos neurológicos relacionados. Reivindicación 32: Una composición farmacéutica caracterizada porque comprende la forma cristalina de acuerdo con las reivindicaciones 2 u 8 - 11 y un diluyente o portador farmacéuticamente aceptable. Reivindicación 33: Una composición farmacéutica de acuerdo con la reivindicación 32, caracterizada porque la forma cristalina es la Forma A libre anhidra.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063060281P | 2020-08-03 | 2020-08-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR123132A1 true AR123132A1 (es) | 2022-11-02 |
Family
ID=77640732
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210102157A AR123132A1 (es) | 2020-08-03 | 2021-08-03 | Formas cristalinas de un inhibidor de la o-glucoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20230286972A1 (es) |
| EP (1) | EP4188925A1 (es) |
| JP (1) | JP2023536911A (es) |
| KR (1) | KR20230061395A (es) |
| CN (1) | CN116917284A (es) |
| AR (1) | AR123132A1 (es) |
| AU (1) | AU2021322186A1 (es) |
| BR (1) | BR112023002013A2 (es) |
| CA (1) | CA3188250A1 (es) |
| CL (1) | CL2023000327A1 (es) |
| CO (1) | CO2023002543A2 (es) |
| CR (1) | CR20230118A (es) |
| IL (1) | IL300365A (es) |
| MX (1) | MX2023001469A (es) |
| PE (1) | PE20231168A1 (es) |
| TW (1) | TW202220984A (es) |
| UY (1) | UY39366A (es) |
| WO (1) | WO2022031701A1 (es) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9206128B2 (en) | 2011-11-18 | 2015-12-08 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| EP2780013A4 (en) | 2011-11-18 | 2015-07-01 | Constellation Pharmaceuticals Inc | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF |
| WO2013078320A1 (en) | 2011-11-21 | 2013-05-30 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| CA2862289C (en) | 2012-02-10 | 2019-11-26 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| WO2014124418A1 (en) | 2013-02-11 | 2014-08-14 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| WO2014151142A1 (en) | 2013-03-15 | 2014-09-25 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| US9969716B2 (en) | 2013-08-15 | 2018-05-15 | Constellation Pharmaceuticals, Inc. | Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof |
| TWI654978B (zh) | 2017-01-27 | 2019-04-01 | 美商美國禮來大藥廠 | 5－甲基－1,2,4－二唑－3－基化合物 |
| MX2021003232A (es) * | 2018-09-19 | 2021-07-16 | Biogen Ma Inc | Inhibidores de o-glicoproteina-2-acetamido-2-desoxi-3-d-glucopiran osidasa. |
-
2021
- 2021-08-03 EP EP21766024.0A patent/EP4188925A1/en active Pending
- 2021-08-03 US US18/019,270 patent/US20230286972A1/en active Pending
- 2021-08-03 TW TW110128540A patent/TW202220984A/zh unknown
- 2021-08-03 CN CN202180066901.9A patent/CN116917284A/zh active Pending
- 2021-08-03 BR BR112023002013A patent/BR112023002013A2/pt unknown
- 2021-08-03 CA CA3188250A patent/CA3188250A1/en active Pending
- 2021-08-03 KR KR1020237007569A patent/KR20230061395A/ko unknown
- 2021-08-03 JP JP2023507579A patent/JP2023536911A/ja active Pending
- 2021-08-03 UY UY0001039366A patent/UY39366A/es unknown
- 2021-08-03 AR ARP210102157A patent/AR123132A1/es unknown
- 2021-08-03 CR CR20230118A patent/CR20230118A/es unknown
- 2021-08-03 PE PE2023000189A patent/PE20231168A1/es unknown
- 2021-08-03 MX MX2023001469A patent/MX2023001469A/es unknown
- 2021-08-03 IL IL300365A patent/IL300365A/en unknown
- 2021-08-03 AU AU2021322186A patent/AU2021322186A1/en active Pending
- 2021-08-03 WO PCT/US2021/044341 patent/WO2022031701A1/en active Application Filing
-
2023
- 2023-02-01 CL CL2023000327A patent/CL2023000327A1/es unknown
- 2023-03-01 CO CONC2023/0002543A patent/CO2023002543A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20230286972A1 (en) | 2023-09-14 |
| EP4188925A1 (en) | 2023-06-07 |
| IL300365A (en) | 2023-04-01 |
| KR20230061395A (ko) | 2023-05-08 |
| WO2022031701A9 (en) | 2022-03-31 |
| TW202220984A (zh) | 2022-06-01 |
| WO2022031701A1 (en) | 2022-02-10 |
| MX2023001469A (es) | 2023-06-16 |
| CR20230118A (es) | 2023-06-02 |
| PE20231168A1 (es) | 2023-07-26 |
| CA3188250A1 (en) | 2022-02-10 |
| JP2023536911A (ja) | 2023-08-30 |
| AU2021322186A1 (en) | 2023-04-06 |
| UY39366A (es) | 2022-02-25 |
| CO2023002543A2 (es) | 2023-06-09 |
| CL2023000327A1 (es) | 2023-10-06 |
| BR112023002013A2 (pt) | 2023-05-02 |
| CN116917284A (zh) | 2023-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021002965A1 (es) | Compuestos antivirales que contienen nitrilo. | |
| CO2021005711A2 (es) | Compuestos de 6-azabencimidazol sustituidos como inhibidores de hpk1 | |
| AR020727A1 (es) | Uso de compuestos derivados 3-amino-4-aril-maleimidas para la preparacion de medicamentos para condiciones asociadas a una necesidad de inhibicion de lagsk-3, dichos compuestos, procedimiento para su preparacion y composiciones farmaceuticas que los comprenden | |
| CL2004000174A1 (es) | Compuestos derivados de malonamida n,n'-disustituidos; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto en el tratamiento de la enfermedad de alzheimer. | |
| PE20070138A1 (es) | Compuestos heterociclicos como inhibidores de aspartil proteasas | |
| RU2008107733A (ru) | Ингибиторы gsk-3 | |
| UY28279A1 (es) | Fenacilo 2 -hidroxi - 3 - diaminoalcanos | |
| AR066972A1 (es) | Derivados azapeptidicos | |
| DOP2004000888A (es) | 2-hidroxi-3-diaminoalcanos de benzamida (benzamide 2-hydroxy-3-diaminoalkanes | |
| CO2022002804A2 (es) | Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos | |
| EA200870577A1 (ru) | Конденсированные трициклические сульфонамидные ингибиторы гамма-секретазы | |
| BR112022007488A2 (pt) | Forma cristalina de base livre de um receptor c5a de componente do complemento | |
| ECSP22086223A (es) | Métodos para fabricar un compuesto bifuncional, formas ultrapuras del compuesto bifuncional y formas de dosificación que comprenden el mismo | |
| CO2022017072A2 (es) | Imidazopiridazinas como moduladores de il-17 | |
| BR0111140A (pt) | Forma polimórfica, composição farmacêutica, métodos para o tratamento de uma doença inflamatória, de uma doença mediada por ciclooxigenase, de dor, e, processo para fabricar um polimorfo de forma v | |
| AR043444A1 (es) | Profarmacos de diaril-2- 5h -furanonas que liberan oxido nitrico como inhibidores de la ciclooxigenasa-2 | |
| BR112023001861A2 (pt) | Composições e métodos para tratamento de doenças e distúrbios | |
| AR126537A1 (es) | Sales y formas en estado sólido de un compuesto inhibidor de kif18a | |
| AR123132A1 (es) | Formas cristalinas de un inhibidor de la o-glucoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa | |
| ECSP024388A (es) | Inhibidores de proteasas | |
| ECSP014079A (es) | Derivados de sulfonamida | |
| GT200100188A (es) | Inhibidores de aminotransferasa que dependen del aminoacido de cadena ramificada y su uso en el tratamiento deenfermedades neurodegenerativas. | |
| PE20230559A1 (es) | Medicamentos antivirales para el tratamiento y prevencion de la infeccion por vih | |
| AR126552A1 (es) | Composición farmacéutica para prevenir o tratar la esclerosis sistémica | |
| ECSP24006915A (es) | Antagonistas del receptor muscarínico 4 y métodos de uso |